Since day one in Congress, Rep. Earl L. “Buddy” Carter (R-GA) has been sounding the alarm on the predatory practices of the pharmaceutical industry’s middlemen, pharmacy benefit managers (PBMs).
Following Rep. Carter’s March, 2022 call with Federal Trade Commission (FTC) Chair Lina Khan, she publicly agreed that PBMs reduce patient’s access to life-saving drugs.
“Finally, the FTC is acknowledging that bad actors in the drug industry are spiking costs for patients without providing them any real value,” said Carter. “No attempts to reduce prescription drug prices will be effective without first going after PBMs. It’s time to fix this broken system.”
Rep. Carter has introduced the bipartisan Drug Price Transparency in Medicaid Act to limit the power of PBMs to artificially spike Medicaid drug prices. This legislation aims to radically decrease drug prices and put power back into the hands of the patients.
Click here to read the full bill.
Original source can be found here.
